Sigma Planning Corp’s GSK GSK Stock Holding History

Sigma Planning Corp’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	21,781 -932	-4%	-$49.3K	0.03%	550
2026 Q1	$1.25M	Sell	22,713 -9,806	-30%	-$531K	0.03%	484
2025 Q4	$1.59M	Buy	32,519 +644	+2%	+$30K	0.04%	380
2025 Q3	$1.38M	Sell	31,875 -1,014	-3%	-$39.6K	0.04%	425
2025 Q2	$1.26M	Sell	32,889 -3,527	-10%	-$135K	0.04%	429
2025 Q1	$1.41M	Buy	36,416 +1,597	+5%	+$58.5K	0.05%	375
2024 Q4	$1.18M	Buy	34,819 +630	+2%	+$22.7K	0.04%	438
2024 Q3	$1.4M	Sell	34,189 -6,074	-15%	-$248K	0.04%	390
2024 Q2	$1.55M	Sell	40,263 -13,513	-25%	-$568K	0.05%	354
2024 Q1	$2.31M	Buy	53,776 +27,528	+105%	+$1.14M	0.07%	273
2023 Q4	$973K	Sell	26,248 -34,600	-57%	-$1.24M	0.08%	275
2023 Q3	$2.21M	Buy	60,848 +457	+0.8%	+$16.2K	0.08%	256
2023 Q2	$2.15M	Sell	60,391 -5,440	-8%	-$195K	0.08%	267
2023 Q1	$2.34M	Buy	65,831 +2,164	+3%	+$75.7K	0.08%	261
2022 Q4	$2.24M	Buy	63,667 +11,802	+23%	+$393K	0.08%	261
2022 Q3	$1.53M	Buy	51,865 +7,305	+16%	+$277K	0.06%	324
2022 Q2	$2.42M	Buy	44,560 +4,761	+12%	+$263K	0.08%	235
2022 Q1	$2.17M	Sell	39,799 -316	-0.8%	-$17.2K	0.06%	294
2021 Q4	$2.21M	Sell	40,115 -3,269	-8%	-$170K	0.06%	306
2021 Q3	$2.07M	Sell	43,384 -392	-0.9%	-$19.7K	0.06%	321
2021 Q2	$2.18M	Buy	43,776 +2,733	+7%	+$131K	0.06%	312
2021 Q1	$1.83M	Buy	41,043 +6,145	+18%	+$279K	0.06%	333
2020 Q4	$1.6M	Sell	34,898 -3,151	-8%	-$145K	0.05%	321
2020 Q3	$1.79M	Buy	38,049 +3,102	+9%	+$155K	0.07%	262
2020 Q2	$1.78M	Buy	34,947 +140	+0.4%	+$7.18K	0.08%	259
2020 Q1	$1.65M	Buy	34,807 +6,564	+23%	+$350K	0.1%	210
2019 Q4	$1.66M	Buy	28,243 +2,407	+9%	+$134K	0.07%	289
2019 Q3	$1.38M	Buy	25,836 +164	+0.6%	+$8.44K	0.07%	299
2019 Q2	$1.28M	Buy	25,672 +200	+0.8%	+$10K	0.07%	294
2019 Q1	$1.33M	Buy	25,472 +1,574	+7%	+$78.7K	0.08%	262
2018 Q4	$1.14M	Sell	23,898 -235	-1%	-$11.6K	0.08%	236
2018 Q3	$1.21M	Sell	24,133 -1,217	-5%	-$61.8K	0.07%	263
2018 Q2	$1.28M	Sell	25,350 -764	-3%	-$38.5K	0.09%	234
2018 Q1	$1.27M	Sell	26,114 -5,703	-18%	-$266K	0.09%	227
2017 Q4	$1.41M	Sell	31,817 -2,127	-6%	-$98.3K	0.11%	213
2017 Q3	$1.72M	Buy	33,944 +552	+2%	+$28K	0.14%	173
2017 Q2	$1.8M	Sell	33,392 -554	-2%	-$29.5K	0.17%	155
2017 Q1	$1.79M	Sell	33,946 -2,655	-7%	-$135K	0.17%	147
2016 Q4	$1.76M	Buy	36,601 +13,623	+59%	+$673K	0.19%	129
2016 Q3	$1.24M	Sell	22,978 -1,516	-6%	-$83.1K	0.15%	165
2016 Q2	$1.33M	Buy	24,494 +630	+3%	+$33.2K	0.17%	146
2016 Q1	$1.21M	Buy	23,864 +624	+3%	+$31.1K	0.17%	142
2015 Q4	$1.17M	Buy	23,240 +2,006	+9%	+$102K	0.16%	144
2015 Q3	$1.02M	Buy	21,234 +2,278	+12%	+$119K	0.16%	152
2015 Q2	$987K	Buy	18,956 +3,012	+19%	+$170K	0.14%	185
2015 Q1	$920K	Sell	15,944 -91	-0.6%	-$5.22K	0.12%	207
2014 Q4	$857K	Buy	+16,035	New	+$897K	0.11%	217

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sigma Planning Corp's GSK Position: Q2 2026 in Review

Sigma Planning Corp reduced its GSK (GSK) stake by 4.1% in Q2 2026, selling an estimated $49.3K and leaving 21,781 shares worth $1.14M. The position accounts for 0.03% of the portfolio, ranked #550.

Sigma Planning Corp first reported a position in GSK in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.42M in Q2 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Sigma Planning Corp held 21,781 shares of GSK worth $1.14M as of Q2 2026.
Sigma Planning Corp sold 932 GSK shares in Q2 2026, an estimated $49.3K.
GSK made up 0.03% of Sigma Planning Corp's portfolio in Q2 2026, its #550 holding.
Sigma Planning Corp first reported a position in GSK in Q4 2014 and has held it in 47 quarters since.
Sigma Planning Corp's GSK position peaked at $2.42M in Q2 2022.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.